Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Adc Therapeutics SA has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. Both of these matters are assigned to 1 distinct examiner and are located within 1 distinct art unit. This indicates a high level of concentration for the company's current prosecution activity.
HILARY ANN PETRASH is the busiest examiner for the portfolio, overseeing 2 pending actions. The fact that a single examiner is managing both of the pending office actions within a single art unit suggests a consistent examination environment. This centralized approach in the Biotechnology & Pharmaceuticals area means that HILARY ANN PETRASH is the primary point of contact for all current pending matters. The prosecution strategy appears unified under a single examiner and art unit, which may simplify the coordination of responses for the company's Biotechnology & Pharmaceuticals applications.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PETRASH, HILARY ANN | 2 | 64.5% | +51.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18969940 | ANTI-PSMA ANTIBODY CONJUGATES | PETRASH, HILARY ANN | 41d |
| 18971848 | ANTI-CLAUDIN-6 CONJUGATES | PETRASH, HILARY ANN | — |
| Art Unit | Apps |
|---|---|
| 1644 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18971848 | ANTI-CLAUDIN-6 CONJUGATES | PETRASH, HILARY ANN | 1644 | §103DP | Non-Final OA | — | Pending | Dec 06, 2024 |
| 18969940 | ANTI-PSMA ANTIBODY CONJUGATES | PETRASH, HILARY ANN | 1644 | §103Other | Non-Final OA | 41d | Pending | Dec 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial